Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma
Open Access
- 1 November 2017
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 152 (11), 1086-1088
- https://doi.org/10.1001/jamasurg.2017.2631
Abstract
DNA mismatch repair status is a well-established biomarker in colorectal cancer and is associated with both a favorable prognosis and excellent response to immunotherapy.1 However, the influence of deficient DNA mismatch repair (dMMR) and microsatellite instability in pancreatic ductal adenocarcinoma (PDAC) remains unknown. The prognosis of PDAC is typically dismal and treatment options are limited, but previous research has suggested that microsatellite instability in resected PDAC specimens may be associated with improved survival.2 Because patients with Lynch syndrome harbor germline defects in mismatch repair genes and have significantly elevated lifetime risks of malignant neoplasms, including PDAC,3 we used this unique patient cohort to establish the clinical behavior and outcomes of dMMR PDAC.Keywords
This publication has 6 references indexed in Scilit:
- Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision MedicineGastroenterology, 2016
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyThe New England Journal of Medicine, 2015
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer ResectionJama-Journal Of The American Medical Association, 2010
- Risk of Pancreatic Cancer in Families With Lynch SyndromeJama-Journal Of The American Medical Association, 2009
- Prognostic value of microsatellite instability in resectable pancreatic cancer.2002